Recent Updates
Recently added Catalysts

Futibatinib

Phase 3

Advanced Solid Tumor | Small Molecules | Oncology |Johnson & Johnson|Trials Updated: Nov 17, 2026

Futibatinib development status

Highest phase Phase 3 run by Taiho Pharmaceutical Co., Ltd. (NCT07710885)
Phase scored for JNJPhase 2
Registered trials 7 across 6 sponsors since Feb 2016

Futibatinib target and mechanism

ModalitySmall Molecules

Also known as TAS-120

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment1,000

FDA Designations

No designations recorded

Futibatinib clinical trials

Futibatinib · 1 trial · 1 indication

Phase 2 1
NCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)Advanced Solid Tumor
RECRUITING1,000 Analytics
PHASE2RECRUITING
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Advanced Solid TumorUnlock trial analytics

Study Endpoints

Primary Endpoints

Overall response rate
From the first dose date of study treatment to first CR or PR, whichever came earlier, up to 12 weeks (Module 1 & 3) and 16 weeks (Module 2)

Proportion of patients with a partial response \[PR\] or complete response \[CR\] per RECIST v1.1.

Secondary Endpoints

Progression free survival (PFS by RECIST 1.1)
From initiation of treatment to objective progression or death from any cause, whichever occurs first, up to two years
Overall Survival
From initiation of treatment to death from any cause, up to two years
Duration of response
From documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death (up to apprixmatelly 6 months).
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Module 1 - AtezolizumabEXPERIMENTALGenomically selected populations will all receive the same drug * Arm 1A: BRCA1 or BRCA2 mutations * Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations * Arm 1C: tumors with POLE mutation, POLD1 mutation * Arm 1D: hypermutated tumors * Arm 1E: tumors with other mutations in DNA-repair genes * Arm 1F: tumors with amplified PDL1 * Arm 1G: tumours with CDK12 mutations Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 120 patients in part B of module 1.
Module 2 - FutibatinibEXPERIMENTALGenomically selected populations will all receive the same drug * Arm 2A: Known pathogenic FGFR1-3 mutations * Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations. * Arm 2C: Highly amplified FGFR1-3 with high FGFR1-3 mRNA (with the exception of gastric and breast cancer) * Arm 2D: Highly amplifiedFGFR1-3 without high FGFR1-3 mRNA (with the exception of gastric and breast cancer) Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 2000 subjects will need to be screened in part A in order to enroll 80 patients in part B of module 2.
Module 3 - AmivantamabEXPERIMENTALGenomically selected populations will all receive the same drug * Arm 3A: kinase domain mutations/ MET fusion-genes (including intragene exon skipping MET-MET fusions) * Arm 3B: MET copy number gain (equivalent CNG ≥6) (exception: colorectal cancer) * Arm 3C: EGFR mutations (exception: primary lung malignancies) Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1725 subjects will need to be screened in part A in order to enroll 69 patients in part B of module 3.

Interventions

NameTypeDescription
AtezolizumabDRUG1200 mg, administered IV, once every 3 weeks
FutibatinibDRUG20 mg administered orally, once daily (QD) continuously in 28-day cycles.
AmivantamabDRUG1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites8

Eligibilty Criteria (PART A - iPROFILER) Inclusion Criteria: 1. Subjects must have histologically or cytologically confirmed malignancy that is metastatic or unresectable, who have progressed to standard therapy, who are receiving a standard anticancer treatment, but no subsequent approved treatme...

Countries:FranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Advanced Solid Tumor")

Recent Changes (Last 90 Days)

MEDIUMNov 17, 2026NCT03767075Primary completion: May 2025 → May 2027